Prot# INCB 18424-258: An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects with Primary Myelofibrosis, Post Essential Thrombocythemia-Myelofibrosis and Post Polycythemia Vera-Myelofibrosis Who Have Platelet Counts of 50x

Project: Research project

Project Details

StatusFinished
Effective start/end date11/1/11 → 11/1/17

Funding

  • PPD Development (INCB 18424-258 // INCB 18424-258)
  • Incyte Corporation (INCB 18424-258 // INCB 18424-258)